Literature DB >> 33224747

The incidence, prevalence, and survival rate of thromboangiitis obliterans in Korea: a retrospective population-based study.

Bareun Choi1, Shin Yi Jang2, Seong-Kyong Kim3, Nari Kim4, Kyeongsug Kim4, Dong Kyu Kim5.   

Abstract

BACKGROUND: Few studies used nationwide data to assess the age-standardized prevalence rate, incidence rate, 10-year survival rate, and death risk of thromboangiitis obliterans (TAO; Buerger's disease).
METHODS: Data for 24,392 patients who had newly diagnoses related to TAO (I73.1) from 2006 through 2017 were extracted from the National Health Insurance Service in Korea. The age-standardized prevalence rate, incidence rate, 10-year survival rate, and death risk of TAO were analyzed.
RESULTS: The mean (standard deviation) age of TAO patients overall was 62.0 (15.7) years; 61.3 (15.4) in males and 63.2 (16.1) in females (P<0.001). The proportion of patients older than 50 years old was about 80% overall. The proportion patients who died of TAO was 28.1%. Overall, the age-standardized prevalence rate of TAO decreased from 11.1 persons per 100,000 persons in 2006 to 8.43 persons in 2017, and overall, the incidence rate of TAO decreased from 6.07 persons in 2006 to 3.38 persons in 2017. The age-standardized prevalence rate and incidence rate in males were higher than that in females. The 10-year survival rate of TAO was about 65% (60.7% in males and 72.5% in females). The adjusted hazard ratio increased significantly with older age, male sex, hypertension, diabetes mellitus, myocardial infarction, heart failure, ischemic stroke, hemorrhagic stroke, chronic kidney disease, and malignant neoplasm.
CONCLUSIONS: The 10-year survival rate of TAO was about 65%. Even though the age-standardized prevalence rate and incidence rate of TAO is decreased during the study period, the adjusted hazard ratio showed significantly increases with age and with male sex after adjustment for comorbidities. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  Prevalence; death risk; incidence; survival; thromboangiitis obliterans (TAO)

Year:  2020        PMID: 33224747      PMCID: PMC7666954          DOI: 10.21037/cdt-20-582

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  14 in total

1.  Association of thromboangiitis obliterans with cigarette and bidi smoking in Bangladesh: a case-control study.

Authors:  M Rahman; A S Chowdhury; T Fukui; K Hira; T Shimbo
Journal:  Int J Epidemiol       Date:  2000-04       Impact factor: 7.196

Review 2.  Thromboangiitis obliterans (Buerger's disease).

Authors:  J W Olin
Journal:  N Engl J Med       Date:  2000-09-21       Impact factor: 91.245

Review 3.  Thromboangiitis obliterans in the 21st century--a new face of disease.

Authors:  Rafał Małecki; Krystyna Zdrojowy; Rajmund Adamiec
Journal:  Atherosclerosis       Date:  2009-02-12       Impact factor: 5.162

Review 4.  Pathology and pathogenesis of Buerger's disease.

Authors:  K Tanaka
Journal:  Int J Cardiol       Date:  1998-10-01       Impact factor: 4.164

5.  The Epidemiologic and Clinical Findings of Patients with Buerger Disease.

Authors:  Kimihiro Igari; Yoshinori Inoue; Takehisa Iwai
Journal:  Ann Vasc Surg       Date:  2015-09-11       Impact factor: 1.466

6.  The Prevalence of Marfan Syndrome in Korea.

Authors:  Shin Yi Jang; Su Ra Seo; Seung Woo Park; Duk Kyung Kim
Journal:  J Korean Med Sci       Date:  2017-04       Impact factor: 2.153

7.  The Trends in Health Life Expectancy in Korea according to Age, Gender, Education Level, and Subregion: Using Quality-Adjusted Life Expectancy Method.

Authors:  Min-Woo Jo; Wanu Seo; So Yun Lim; Minsu Ock
Journal:  J Korean Med Sci       Date:  2018-11-02       Impact factor: 2.153

8.  Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients.

Authors:  Alexandre Le Joncour; Simon Soudet; Axelle Dupont; Olivier Espitia; Fabien Koskas; Philippe Cluzel; Pierre Yves Hatron; Joseph Emmerich; Patrice Cacoub; Matthieu Resche-Rigon; Marc Lambert; David Saadoun
Journal:  J Am Heart Assoc       Date:  2018-12-04       Impact factor: 5.501

9.  The Incidence and Prevalence of Thromboangiitis Obliterans in Taiwan: A Nationwide, Population-based Analysis of Data Collected from 2002 to 2011.

Authors:  Jie-Fu Zheng; Yi-Ming Chen; Der-Yuan Chen; Ching-Heng Lin; Hsin-Hua Chen
Journal:  Clinics (Sao Paulo)       Date:  2016-07       Impact factor: 2.365

10.  A Non-smoking Woman with Anti-phospholipid Antibodies Proved to Have Thromboangiitis Obliterans.

Authors:  Natsuki Shima; Yoichiro Akiyama; Shotaro Yamamoto; Ayako Kokuzawa; Katsuya Nagatani; Masahiro Iwamoto; Daisuke Matsubara; Shigeo Kawai; Kojiro Sato; Seiji Minota
Journal:  Intern Med       Date:  2019-10-07       Impact factor: 1.271

View more
  1 in total

1.  Impact of Atrial Fibrillation on Survival in Adults with Congenital Heart Disease: a Retrospective Population-based Study.

Authors:  Shin Yi Jang; June Huh; Eun Kyoung Kim; Sung A Chang; Jinyoung Song; I Seok Kang; Seung Woo Park
Journal:  J Korean Med Sci       Date:  2021-02-01       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.